The Rails: India’s Policies, Incentives, and Corridors Linking Labs to Global Markets

India’s biotech growth story is no longer just about manufacturing scale; it is about whether policy can convert that scale into sustainable innovation. Hyderabad’s Genome Valley shows how clusters are moving into cell and gene therapy, but the bigger picture lies in the national policy stack—BioE3’s biomanufacturing hubs, DBT/BIRAC’s translational platforms, PLI schemes, and Bulk Drug Parks—all backed by budget allocations that stretch further in India’s PPP context than raw figures suggest. Layered on top are connectivity plays like the India–Middle East–Europe Economic Corridor (IMEC), designed to cut transit times and secure cold-chain flows to Europe and the Gulf.

Together, these incentives and corridors are less about subsidies and more about building rails: structures that de-risk innovation, anchor supply chains, and tie Indian biotech into global markets. The question now is not whether India can supply, but how fast these policy rails can carry the sector toward its 2030 goal of becoming a diversified, innovation-driven hub.

From Scale to Sophistication — Hyderabad’s Bet on Next-Gen Biotech

Hyderabad’s Genome Valley is beginning to stretch beyond its traditional base of vaccine and bulk drug production into advanced therapy platforms. In early 2025, Bharat Biotech inaugurated a $75 million cell and gene therapy and viral vector facility, India’s first vertically integrated site designed to produce adeno-associated virus, lentivirus, and adenovirus vectors at scale. The company has already mapped a pipeline of five platform products, including CAR-T, CAR-NK, and off-the-shelf gene therapies, with launches targeted by 2028.

Around the same time, global tools provider Miltenyi Biotec expanded its footprint by opening India’s first dedicated CGT Center of Excellence in Hyderabad, offering training and development capabilities that connect proof-of-concept research to clinical applications. Complementing these moves, Agilent Technologies opened a biopharma experience center in the city to provide advanced lab infrastructure and regulatory-ready workflows for local companies. These investments suggest a gradual pivot: the cluster is no longer only a scale-up powerhouse but is positioning itself as a platform for India’s entry into next-generation biotech.

This shift in Hyderabad mirrors broader national ambitions. The Telangana state government recently valued the life sciences sector anchored by Genome Valley at more than ₹54,000 crore (around $6–7 billion) and highlighted over 250 USFDA-approved sites in the region as proof of regulatory depth. At the national level, India’s Draft Life Sciences Policy 2025–2030 sets targets of reaching a $120 billion market by 2030, expanding CGT and biologics manufacturing capacity, and creating 400,000 new jobs. These measures align with India’s National Bioeconomy Growth Strategy, which emphasizes scaling innovation, digital health integration, and sustainable biomanufacturing.

International frameworks provide another layer. India is a key node in the India–Middle East–Europe Economic Corridor (IMEC), a strategic trade route designed to shorten supply chains, link ports, and enable smoother regulatory pathways across continents. For biotech, this means vaccines, biologics, and emerging therapies manufactured in hubs like Hyderabad could reach Europe and the Middle East with fewer bottlenecks. Trade initiatives such as the U.S.–India Critical and Emerging Technology (iCET) partnership and collaborations with the EU on pharmaceutical standards also reinforce India’s role as both a reliable manufacturer and an aspiring innovation hub. Together, these policy levers knit regional clusters like Genome Valley into global value chains, showing how India’s biotech ambitions are increasingly framed not just as domestic growth stories but as pillars of international trade and health security.

India’s Key Schemes & Policies with Biotech Infrastructure Incentives

Policy Stack: From BioE3 to PLI — and Why It Matters for 2030

India’s policy push reflects an attempt to move from sheer production volume to higher-value innovation and resilience. The BioE3 policy (Biotechnology for Economy, Environment, and Employment), cleared by the Cabinet in August 2024, targets sustainable biomanufacturing and ties directly to a circular bioeconomy. In practice, this has meant DBT and BIRAC launching high-performance biomanufacturing platforms that allow startups and researchers to scale processes from lab to pilot plants more quickly. The aim is not only greener production but also greater independence from external supply shocks.

Complementing this, the National Biopharma Mission—co-funded with the World Bank—continues to de-risk early development for vaccines, biosimilars, devices, and diagnostics. By sharing development risk and validation costs, it lowers barriers for Indian firms to move candidates through preclinical and early clinical stages, a critical gap where many projects would otherwise stall.

On the manufacturing front, Production-Linked Incentive (PLI) schemes and Bulk Drug Parks in Gujarat, Himachal Pradesh, and Andhra Pradesh are designed to localize APIs and key starting materials, cutting dependence on imports from China. For global partners, this signals that India can anchor more of the supply chain domestically while still meeting international regulatory standards.

Budget signals add further weight. The DBT’s Interim Budget allocation of ₹2,251.52 crore in 2024–25 (≈ US$270 million) signals continued priority for life sciences. In absolute terms, that figure is modest compared with U.S. or EU research budgets, but on a purchasing power parity (PPP) basis it stretches further: lab construction, manpower, and clinical trial costs in India can run at 30–50% of Western equivalents. Practically, this means that what looks like a mid-tier line item internationally can finance substantial infrastructure expansion and translational programs domestically.

Hence, policy sets the rails. The pace of implementation and uptake—measured in the number of INDs filed, GMP sites certified, and export volumes secured—will show how fast the train is moving toward India’s 2030 goal of becoming a diversified, innovation-driven biotech hub.

Connectivity & Supply Chains: Why IMEC Keeps Showing Up in Boardrooms

Infrastructure on the ground only tells part of the story. For India’s biotech ambitions to scale globally, connectivity and logistics matter just as much as labs and policies. The India–Middle East–Europe Economic Corridor (IMEC) is pitched as a sea-rail-digital spine linking Indian gateways to Europe via the Gulf and the Mediterranean. For high-value, temperature-sensitive bioproducts—vaccines, biologics, and clinical samples—shorter transit times and predictable routes directly translate into lower cold-chain costs and faster regulatory turnarounds. The digital component matters too: smoother corridors for clinical and regulatory data could help Indian trials integrate more closely with European and Gulf regulators.

The reality, however, remains uneven. In 2025, Indian diplomats continued to court European partners even as regional tensions in West Asia slowed the corridor’s rollout. Analysts increasingly describe IMEC less as an immediate solution and more as a hedging instrument—a way to complement India–UAE trade integration initiatives, from virtual customs clearance to UPI acceptance and logistics hubs in Dubai and Abu Dhabi. For biotech firms, even partial success has value: any corridor that trims days off transit or reduces exposure to chokepoints like the Suez Canal and the Red Sea strengthens India’s case as a reliable exporter of both therapies and clinical expertise.

Taken together, Genome Valley’s rise, the national policy stack, and connectivity plays like IMEC underscore a single point: India is not only building production capacity but embedding itself in the global value chain. From DBT’s budget allocations and BioE3’s biomanufacturing hubs to PLI incentives and international corridors, the direction is clear—India is laying the rails for a biotech ecosystem that aspires to move beyond “pharmacy of the world” toward a durable role as an innovation-driven hub by 2030. The speed at which those rails translate into market-ready products and reliable cross-border flows will determine how far and how fast the train runs.

Author

Bernice Lottering